Current position

George Soros’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2000Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares995.50KHighest verified quarter-end share count
Quarters reported17Verified quarters with shares above zero
What happened?

Soros Fund Management first reported Eli Lilly in Q1 2000. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Soros Fund Management currently reports 22.20K shares. The latest verified filing showed: No change.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
No change22.20K shares reported
Filing context

Quarter-end price $1,199.43 · Estimated holding basis $1,074.68

Q1 2026
Sold 0.6% of the position−135 shares · 22.20K shares remained
Filing context

Quarter-end price $919.77 · Estimated holding basis $1,074.68

Q4 2025
New position+22.33K shares · 22.33K shares reported
Filing context

Quarter-end price $1,074.68 · Estimated holding basis $1,074.68

Q1 2025
Sold the entire position−33.64K shares · No shares reported at quarter-end
Q4 2024
New position+33.64K shares · 33.64K shares reported
Filing context

Quarter-end price $772.00 · Estimated holding basis $772.00

Q1 2024
Sold the entire position−33.00K shares · No shares reported at quarter-end
Portfolio importance

How important is Eli Lilly in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.3%Q2 2026
Current rank#84of 254 reported positions
Peak portfolio weight0.9%Q2 2000
Best historical rank#26Q2 2000
At peak importanceQ2 2000
LLY
0.9%
Largest holding
5.5%
Cross-investor discovery

Who else owns Eli Lilly?

Also reported by 4 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
LLY0.6% of reported portfolio
Ray DalioBridgewater Associates, LP
LLY0.4% of reported portfolio
Stanley DruckenmillerDuquesne Family Office
LLY0.3% of reported portfolio
Explore Eli Lilly across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,115.702026-09-11

Market context only; not an investor transaction price.

Latest filing quarter-end price$1,199.43Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$1,074.68Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Eli Lilly stock page →

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.